#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cervix carcinoma recurrent Ovarian epithelial cancer Fungal infection Vulval cancer Autoinflammation with infantile enterocolitis Neuroendocrine tumour Amyotrophic lateral sclerosis Antiphospholipid syndrome Li-Fraumeni syndrome Glomerulonephritis chronic Lymphoma Lymphatic malformation Glomerulonephritis membranoproliferative Hereditary angioedema Cholangiocarcinoma More trials…

    Learn about Rare Diseases

    Behcet’s syndrome Arterial tortuosity syndrome – Life with Disease Leukoencephalopathy – Treatment Familial haemophagocytic lymphohistiocytosis – Life with Disease Von Willebrand’s disease – Life with Disease Carcinoid syndrome – Trials in Disease Mantle cell lymphoma stage II – Diagnostics Rhabdoid tumour – Treatment Hairy cell leukaemia recurrent – Treatment Niemann-Pick disease – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ht-29-A Sultiame 534 Ocrelizumab ROPINIROLE Triheptanoin Methyl Aminolevulinate Oxybuprocaine Hydrochloride GSKVX000000070965 Efzofitimod Melphalan Hydrochloride Insulin Icodec Clavulanic Acid Ipn01194 Vericiguat Saline Risankizumab Clozapine Ubamatamab Citric Acid More therapies…

    Learn about Your Condition

    Mucosal inflammation Peritoneal neoplasm Lymphangioma Thymic carcinoma Henoch-Schonlein purpura Inborn error of metabolism Acoustic neuroma Thrombocytosis Basal cell naevus syndrome Autism spectrum disorder Cervix carcinoma Bronchitis Aortic aneurysm Cutaneous T-cell lymphoma Mantle cell lymphoma stage IV More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Jean Perrin

Centre Jean Perrin

58 Rue Montalembert, Clermont Ferrand, 63000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Use of 64Cu-PSMA I&T to Detect Lymph Node Spread in Men with Newly Diagnosed Prostate Cancer Before Surgery

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • 64CU-PSMA I&T
    France Italy Spain

  • Study of PF-06821497 with Enzalutamide for Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    • Prostate cancer metastatic
    Investigated Drugs:
    • 5,8-Dichloro-2-[(4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy(Oxetan-3-Yl)Methyl]-3,4-Dihydroisoquinolin-1(2H)-One
    • Dexamethasone
    • Docetaxel
    Czechia France Germany Greece Hungary Italy +5

  • Study on Treating Metastatic Castration-Resistant Prostate Cancer with 177Lu-PNT2002 Compared to Abiraterone or Enzalutamide for Patients After Hormonal Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • [N-{(4R)-4-Carboxy-Κo-4-[4,7,10-Tris(Carboxy-Κ3O4,O7,O10-Methyl)-1,4,7,10-Tetraazacyclododecan-1-Yl-Κ4N1,N4,N7,N10]Butanoyl}-3-Iodo-D-Tyrosyl-D-Phenylalanyl-N6-(8-{N2-[(L-Glutamic Acid-N-Yl)Carbonyl]-L-Lysin-N6-Yl}-8-Oxooctanoyl)-D-Lysinato(3−)](177Lu)Lutetium
    • Gozetotide
    • Abiraterone
    France The Netherlands Sweden

  • Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    Investigated Drugs:
    • Pf-07220060 Monohydrate
    • Everolimus
    • Exemestane
    Belgium Bulgaria Czechia Denmark Finland France +8

  • Study of Debio 4228 for Patients with Advanced or Metastatic Prostate Cancer

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Degarelix
    Belgium Bulgaria France Italy Lithuania Poland +1

  • Study on Pausing Treatment with Pembrolizumab and Axitinib in Patients with Metastatic Kidney Cancer at Good or Intermediate Risk

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Cabozantinib
    • Lenvatinib
    France

  • Study on the Effects of Methylprednisolone and Isavuconazonium Sulfate in Immunocompromised Patients with Acute Respiratory Failure of Unknown Cause

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Respiratory failure
    Investigated Drugs:
    • Isavuconazonium Sulfate
    • Methylprednisolone
    France

  • Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Cisplatin
    • Nivolumab
    Belgium France Greece Poland Spain

  • Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    • Malignant melanoma
    • Oesophageal squamous cell carcinoma
    Investigated Drugs:
    • Cemiplimab
    • Avelumab
    • Atezolizumab
    France

  • Study on Capivasertib and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    • Prostate cancer
    • Prostate cancer metastatic
    Investigated Drugs:
    • Capivasertib
    • Docetaxel
    Belgium Czechia France Greece Hungary The Netherlands +2
Previous Page
1 … 10 11 12 13 14 … 20
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!